Introduction
============

Lung Adenocarcinoma, a subtype of non-small cell lung cancer is the most pervasive among lung cancers leading to the death of millions of people each year [@B1], [@B2]. Though the recent therapy for the lung adenocarcinoma with mutated EGFR and rearranged ALK have been significant [@B3], [@B4], but the other driving force for the progress of lung adenocarcinoma have not been deciphered much. The type of interaction among the gene and its environment decides their role in disease progression [@B5], [@B6]. Understanding the gene interactions and its importance in the regulation mechanism is necessary to identify a potential target for therapeutic application.

In this study, we analyzed the expression of Y- box binding protein 1 (YBX1) and its interactors in lung adenocarcinoma (LUAD). YBX1 belongs to the Y-box binding protein family with a highly conserved cold shock domain and known to be involved in various eukaryotic cellular mechanisms [@B7]-[@B9]. YBX1 is usually involved in RNA splicing and translational mechanism in cytoplasm but, it translocates to nucleus and gets involved in transcriptional regulation during stress condition [@B10]-[@B13]. It is associated with drug resistance, cell proliferation and cell death [@B14]. The transcription factor of YBX1 binds to the E-box for regulating it [@B15].

YBX1 is over expressed in various cancers and it has been suggested as biomarker in prognosis of various cancer types [@B16], [@B17]. Multi drug resistance and metastasis are major reason for it\'s over expression [@B18], [@B19]. YBX1 interactors are known to be involved in various cellular mechanisms ranging from cell signaling, DNA and protein repair mechanism to transcriptional regulation [@B20]-[@B26]. Genes which are known to be involved in regulation of YBX1 as well as those regulated by YBX1 has been listed in (Table [1](#T1){ref-type="table"}).

In this study we investigated the role of YBX1 and its interactors in Lung adenocarcinoma by looking at their expression profile and constructed gene regulatory network in order to decipher their importance in network formation by a system biological approach.

Materials and Methods
=====================

RNA Seq data and Sample Quality Analysis
----------------------------------------

The Cancer Genome Atlas (TCGA) RNA-Seq level 3 data for YBX1 and its interactors belonging to 116 normal and normal matched tumor samples in LUAD were downloaded from Broad Genome Data Analysis Center (GDAC) Firehose site (<https://gdac.broadinstitute.org/>). RNA Sequence by Expectation Maximization (RSEM) [@B69] counts for 57 genes of our interest including YBX-1 were used for differential expression analysis.

Principle Component Analysis (PCA) and hierarchical clustering with log transformed datasets of the samples were performed using R-Bioconductor [@B70],[@B71] package DESeq2 [@B72] to estimate sample dispersion and to filter out the outlier.

Differential Expression (DE) Analysis and Correlation between genes
-------------------------------------------------------------------

R-Bioconductor package DESeq2 was used to carry out differential expression analysis with nbionom Wald test for calculating logarithmic fold change and Benjamini- Hochberg method [@B73] for estimating adjusted-p value. Genes with adjusted-p value less than 0.05 were considered as differentially expressed. Correlation between differentially expressed genes was calculated with Pearson Correlation method using R package Hmisc [@B74] and the plot for the correlation coefficient was constructed using R package Corrplot [@B75].

Gene Regulatory Network Construction and Analysis
-------------------------------------------------

Gene regulatory network was constructed for the 56 genes omitting GAS5 using the GeneMANIA [@B76] with maximum resultant gene and attributes to enrich were 30 and 215 respectively. And the constructed network was analyzed for its network topology by looking at its parameters like closeness centrality, betweenness centrality and degree with network analysis tool in Cytoscape 3.4 [@B77]. RAIN (RNA - protein Association and Interaction Network) [@B78] was used to identify interactors for the long non-coding RNA (lncRNA) GAS5. And Search Tool for Retrieval of Interacting Genes (STRING) database [@B79] was used to analyze the network and the interactions with confidence level of 0.7 were considered significant. Network with not more than 10 interactors for the GAS5 was constructed.

Gene Set Enrichment Analysis
----------------------------

Functional enrichment for the genes common to both differentially expressed gene sets and hub genes from network was done by using Database for Annotation, Visualization and Integrated Discovery (DAVID) [@B80]. Gene Ontology (GO) database [@B81] provides the annotation for the gene set and Reactome pathway [@B82] illustrate the pathways in which the genes were involved. With DAVID tool we analyzed the gene set in both GO and Reactome pathway with p-value \< 0.05 and gene-count \> 3 as condition for enrichment analysis.

Results
=======

Assessment of Sample Quality and Filtering
------------------------------------------

In this study, we initially took 116 LUAD samples with TCGA level-3 data. With Principle Component Analysis (PCA) and hierarchical clustering removed samples whichever showed variation within its group (Figure [S1](#SM0){ref-type="supplementary-material"}). And we plotted again PCA and hierarchical clustering for the final 95 samples with 57 genes. After filtering, two methods now able to distinguish the samples based on their conditions- normal or tumor (Figure [1](#F1){ref-type="fig"}).

Differential Expression Analysis and Correlation between Genes
--------------------------------------------------------------

The 43 genes which have adjusted-p value less than 0.05 were selected as differentially expressed with GATA1 having a high negative fold change (-1.91476) and MMP13 having a high positive fold change (5.81790). And correlation matrix between the differentially expressed genes was constructed and the correlation coefficient with p-value less than 0.05 **were** considered significant (Figure [2](#F2){ref-type="fig"}). YBX1 showed a maximum positive correlation with C1QBP (0.592) and negative correlation with HLA-E (-0.281) (Table [S1](#SM0){ref-type="supplementary-material"}).

Gene Network Construction and Analysis
--------------------------------------

Gene network was constructed and analyzed (Figure [3](#F3){ref-type="fig"}), it has 86 nodes and 3611 interactions (Table [2](#T2){ref-type="table"}). Top 10 genes involved in the network formation were selected based on the topology parameter-degree, betweenness centrality and closeness centrality (Table [3](#T3){ref-type="table"})**.** The attributes from GeneMANIA showed cancer pathways hold 15.34% in network with involvement of 17 genes (Table [4](#T4){ref-type="table"}).

As GeneMANIA construct network and interactions for the coding gene, it was not able to predict for GAS5. So RAIN database which identify the interactors for non-coding RNA was used to identify interactors of GAS5. Total 10 interactors were found and the network was constructed between the genes with confidence level of 0.7 using STRING database (Figure [4](#F4){ref-type="fig"})

Gene Set Enrichment Analysis
----------------------------

The annotation of the gene with GO and Reactome pathways using DAVID resulted in a single cluster with genes enriched in GO- cellular components of proteinaceous extracellular matrix and extracellular region. GO- Biological process contained the collagen catabolic process and Reactome pathways included Generic transcriptional regulation. Only 3 genes were involved in the enrichment when the condition for enrichment was made high, namely- COL1A2, MMP12, MMP13. The enriched terms are shown in **Table [5](#T5){ref-type="table"}**.

Discussion
==========

Despite of various studies carried out on YBX1, role of its interactors in lung adenocarcinoma have been less explored. YBX1 have been involved in the regulation of tumor progression in lung adenocarcinoma [@B83], [@B84], so understanding its interactions with other gene become a necessary to know their mechanism in disease progression and drug discovery. Our present study finds that YBX1 is up regulated with a low fold change (0.224). GATA 1 and GATA 2 which upregulate YBX1 level in erythroid cells [@B20] were found to be down regulated that indicates that they don\'t play major role in regulation of YBX1 in lung adenocarcinoma.

Among the genes which upregulate YBX1, PABPC1 which is involved in the translation of YBX1 mRNA [@B85] was found to be having high correlation (\> 0.4) with YBX1 and it was significantly expressed with a fold change of 1.259. C1QBP which is known to be involved in prostate cancer progression [@B86] and a highly negative regulator of YBX1 in renal cell carcinoma [@B87] is highly correlated with YBX1 along with GAS5, a long non-coding RNA which involves in regulating cell death in prostate cancer [@B88]. Among the GAS5 interactors identified from RAIN database there are two proteins namely Growth Arrest Specific 2 (GAS2) and Peripheral myelin protein 22 (PMP22) which are known to be over expressed in colorectal cancer cell and breast cancer patients [@B89], [@B90] respectively. However the evidence regarding their role in LUAD disease progression needs to be explored for being a potential biomarker in LUAD identification and for therapeutic application.

Comparison of the differentially expressed genes and the hub genes in the network formation revealed that MMP13, ABCC2, MMP12, TSHR, COL1A2, PABPC1 and YBX1 are common among the both groups. Except for PABPC1, rest of the genes are usually repressed by YBX1, but in our study they are among the highly up regulated genes making a need for further study to understand their relationship between YBX1 in LUAD. Among the three genes involved in the enrichment, MMP12 and MMP13 are reported to be involved in the lung cancer in earlier studies [@B90]- [@B94]. Significantly COL1A2 is involved in progress of gastric cancer [@B95] and in head and neck cancer [@B96]. It can serve as a potential biomarker in LUAD and its involvement in the disease progress need to be explored.

Conclusion
==========

The study aimed to investigate the role of YBX1 and its interactors in lung adenocarcinoma by looking at their differential expression and network topology study. The study showed PABPC1 can be potential target in regulating YBX1. The lncRNA GAS5, whose role in the LUAD need to be explored and it can be a potential biomarker along with COL1A2.

Supplementary Material {#SM0}
======================

###### 

Supplementary figures and tables.
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Click here for additional data file.
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###### 

**Quality of the samples after filtering**. (1A) Heatmap shows the unsupervised hierarchical clustering of the normal and tumor samples in LUAD after filtration. The row represents the genes and column represent the samples. Normal and tumor samples are clustered within their group based on their Euclidean distance. (1B) Principle Component Analysis for the filtered samples shows that first principle component (PC1) separates the normal and tumor samples. In both analysis, samples are found to be grouped within their type.

![](jgenv06p0103g001)
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![**Correlation plot between the differentially expressed genes in LUAD**. Correlation with the significance p- value (\<0.05) are shown. Insignificant correlation are left blank without colors.](jgenv06p0103g003){#F2}

###### 

**Gene network constructed and analyzed with Cytoscape**. Directed root network built from the gene interaction data obtained from GeneMANIA. Network has 86 nodes with 3611 interactions. **Figure [3](#F3){ref-type="fig"}A**, **3B** and **3C** highlights the top 10 genes with closeness centrality, betweenness centrality and degree respectively. CDKN1A is the common gene between closeness centrality and betweenness centrality. Five genes namely, HLA-DRA, HLA-A, HLA-DRB1, HLA-DMB and B2M showed highest betweenness centrality and degree.
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![**Interactors of GAS5 derived from RAIN database**. Interaction with confidence level \> 0.7 is considered as significant. Among the interactors GAS2 and PMP22 are the proteins involved in interaction with GAS5.](jgenv06p0103g007){#F4}

###### 

Genes regulates and regulated by YBX1

  Gene- Id                                 Gene                                                                      Reference
  ---------------------------------------- ------------------------------------------------------------------------- ---------------
  **Genes Up- Regulates YBX1 \| 4904**                                                                               
  TP73 \| 7161                             Tumor Protein 73                                                          [@B17]
  MYC \| 4609                              v-myc avian myelocytomatosis viral oncogene homolog                       
  MAX \| 4149                              MYC Associated Factor X                                                   
  TWIST1 \| 7291                           Twist basic helix-loop-helix transcription factor 1                       [@B14]
  PABPC1 \| 26986                          Poly(A) binding protein, cytoplasmic 1                                    [@B18]
  GATA1 \| 2623                            GATA binding protein 1                                                    [@B19]
  GATA2 \| 2624                            GATA binding protein 2                                                    
  PTGER1 \| 5731                           Prostaglandin E receptor 1 (subtype EP1)                                  [@B20]
  SHH \| 6469                              Sonic Hedgehog                                                            [@B21]
  **Genes Down- Regulates YBX1 \| 4094**                                                                             
  FOXO3 \| 2309                            Forkhead Box 03                                                           [@B15]
  ILK \| 3611                              Integrin linked kinase                                                    [@B16]
  TGFB1 \| 7040                            Transforming growth factor, beta 1                                        [@B22]
  C1QBP \| 708                             Complement component 1, q subcomponent binding protein                    [@B23]
  GAS5 \| 60674                            Long non coding RNA growth arrest specific transcript 5                   [@B24]
  KAT2B \| 8850                            K (lysine) acetyltransferase 2B                                           [@B25]
  **Genes Activated by YBX1 \| 4904**                                                                                
  CCL5 \| 6352                             Chemokine (C-C motif) ligand 5                                            [@B26],[@B27]
  CD44 \| 960                              CD44 molecule                                                             [@B28]
  ITGA6 \| 3655                            Integrin, alpha 6                                                         
  MMP2 \| 4313                             Matrix metallopeptidase 2                                                 [@B29],[@B30]
  POLA1 \| 5422                            Polymerase (DNA directed), alpha 1, catalytic subunit                     [@B31]
  EGFR \| 1956                             Epidermal growth factor receptor                                          [@B32]
  ERBB2 \| 2064                            V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2           
  MET \| 4233                              Met proto-oncogene                                                        [@B33]
  ABCB1 \| 5243                            ATP-binding cassette, sub-family B (MDR/TAP), member 1                    [@B34],[@B35]
  MVP \| 9961                              Major vault protein                                                       [@B36]
  PDGFB \| 5155                            Platelet-derived growth factor beta polypeptide                           [@B37]
  PTPN1 \| 5770                            Protein tyrosine phosphatase, non-receptor type 1                         [@B38]
  SMAD7 \| 4092                            SMAD family member 7                                                      [@B39]
  CCNA1 \| 8900                            Cyclin A1                                                                 [@B40]
  CCNA2 \| 890                             Cyclin A2                                                                 
  CCNB1 \| 891                             Cyclin B1                                                                 
  PIK3CA \| 5290                           Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha   [@B41]
  **Genes Repressed by YBX1 \| 4904**                                                                                
  ACTA1 \| 58                              Actin, alpha 1, skeletal muscle                                           [@B42],[@B43]
  COL1A1 \| 1277                           Collagen, type I, alpha 1                                                 [@B44],[@B45]
  COL1A2 \| 1278                           Collagen, type I, alpha 2                                                 [@B46]
  CPS1 \| 1373                             Carbamoyl-phosphate synthase 1, mitochondrial                             [@B47]
  FAS \| 355                               Fas cell surface death receptor                                           [@B5]
  CSF2 \| 1437                             Colony stimulating factor 2 (granulocyte-macrophage)                      [@B48],[@B49]
  HSPA5 \| 3309                            Heat shock 70kda protein 5                                                [@B50]
  MMP12 \| 4321                            Matrix metallopeptidase 12                                                [@B51]
  MMP13 \| 4322                            Matrix metallopeptidase 13                                                [@B52]
  HLA-A \| 3105                            Major histocompatibility complex, class I, A                              [@B53]
  HLA-B \| 3106                            Major histocompatibility complex, class I, B                              
  HLA-C \| 3107                            Major histocompatibility complex, class I, C                              
  HLA-E \| 3133                            Major histocompatibility complex, class I, E                              
  HLA-F \| 3134                            Major histocompatibility complex, class I, F                              
  HLA-G \| 3135                            Major histocompatibility complex, class I, G                              
  HLA-DRA \| 3122                          Major histocompatibility complex, class II, DR alpha                      [@B54]-[@B56]
  B2M \| 567                               Beta-2-microglobulin                                                      
  HLA-DQB1 \| 3119                         Major histocompatibility complex, class II, DQ beta 1                     
  ABCC2 \| 1244                            ATP-binding cassette, sub-family C (CFTR/MRP), member 2                   [@B57]
  CDKN1A \| 1026                           Cyclin-dependent kinase inhibitor 1A (p21, Cip1)                          [@B58]
  TP53 \| 7157                             Tumor protein p53                                                         [@B59]
  TSHR \| 7253                             Thyroid stimulating hormone receptor                                      [@B60]
  VEGFA \| 7422                            Vascular endothelial growth factor A                                      [@B61],[@B62]
  SOX2 \| 6657                             SRY (sex determining region Y)-box 2                                      [@B63]

###### 

Interaction type and number of interactions in the network constructed by GeneMANIA

  Type of Interactions    Number of Interactions
  ----------------------- ------------------------
  Co-expression           1761
  Co-localization         116
  Genetic Interaction     98
  Pathways                182
  Physical Interaction    462
  Predicted               13
  Shared Protein Domain   979

###### 

Central genes in Gene Regulatory network constructed using GeneMANIA and analyzed by Cytoscape- Network Analysis Tool. Top 10 gene with high Closeness Centrality, Betweenness Centrality and Degree.

  Genes    Closeness Centrality   Genes      Betweenness Centrality   Genes      Degree
  -------- ---------------------- ---------- ------------------------ ---------- --------
  MMP13    1.000                  HLA-DRA    0.018                    HLA-DRA    317
  YBX-1    1.000                  B2M        0.017                    HLA-DMA    274
  TSHR     1.000                  HLA-A      0.015                    HLA-A      266
  ABCC2    0.800                  HLA-C      0.014                    HLA-DPB1   266
  KATA2B   0.750                  CDKN1A     0.014                    HLA-DPA1   257
  ABCB1    0.750                  ILK        0.014                    B2M        255
  COL1A2   0.700                  HLA-B      0.010                    HLA-G      252
  CDKN1A   0.689                  HLA-DMB    0.010                    HLA-DMB    246
  MMP 12   0.667                  VEGFA      0.009                    HLA-F      241
  MYC      0.667                  HLA-DRB1   0.008                    HLA-DRB1   226

###### 

Genes involved in Cancer Pathways, known from GENEMANIA network attributes.

  Gene Id          Gene
  ---------------- -------------------------------------------------------------------------
  CCNAI \| 8900    Cyclin A
  VEGFA \| 7422    vascular endothelial growth factor A
  MMP2 \| 4313     Matrix Metallopeptidase 2
  MET \| 4233      Met proto-oncogene
  MAX \| 4149      MYC associated factor X
  SHH \| 6469      Sonic hedgehog
  TGFB1 \| 7040    Transforming Growth Factor, Beta 1
  ITGA6 \| 3655    Integrin, alpha 6
  FAS \| 355       Fas cell surface death receptor
  TP53 \| 7157     Tumor Protein p53
  PDGFB \| 5155    Platelet-derived growth factor beta polypeptide
  CDKN1A \| 1026   Cyclin-dependent kinase inhibitor 1A
  ERBB2 \| 2064    v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
  PIK3CA \| 5290   Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha
  EGFR \| 1956     Epidermal growth factor receptor
  CDKN1B \|        Cyclin-dependent kinase inhibitor 1B

###### 

Gene Enrichment Analysis- Gene Ontology (GO) and Reactome Pathways (RP) enriched by genes common to differential expression and hub gene in the gene regulatory network.

  Group   Term                                             Gene Count   p-value
  ------- ------------------------------------------------ ------------ ----------
  GO-BP   GO:0030574\~collagen catabolic process           3            1.419E-4
  GO-CC   GO:0005578\~proteinaceous extracellular matrix   3            0.002
  GO-CC   GO:0005576\~extracellular region                 3            0.065
  RP      R-HSA-1442490:R-HSA-1442490                      3            4.829E-4
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